COST (COvid STudio) ACTION: Study for the Evaluation of Specific Antibodies Anti Covid-19 Linked to Covid-19 Infection, Symptoms and Genetic Expression of ACE2 Polymorphisms in Patients (COST ACTION)
NCT ID: NCT04367402
Last Updated: 2020-04-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
600 participants
OBSERVATIONAL
2020-03-30
2020-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Symptomatic Patients
Patients who had symptoms related to COVID-19 infection
BioMedomics COVID-19 IgM-IgG Rapid Test
Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
Health people
Healthy people who never had syntomps related to COVID-19 infection
BioMedomics COVID-19 IgM-IgG Rapid Test
Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
Asyntomatic Individuals
Asyntomatic people to recruit after the restriction have ended
BioMedomics COVID-19 IgM-IgG Rapid Test
Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
BioMedomics COVID-19 IgM-IgG Rapid Test
Qualitative test to aid in the diagnosis of COVID-19 novel coronavirus
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* mentally incapacitated.
18 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Azienda Ospedaliera San Paolo
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Stefano Centanni
Full Professor
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AO San Paolo
Milan, IT, Italy
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Stefano Centanni, Full Professor
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020/ST/057
Identifier Type: -
Identifier Source: org_study_id